The value of prostate cancer screening remains controversial because of the high prevalence of the disease and the fact that many tumors detected through screening are not destined to lead to morbidity or mortality, rendering
Scott A. Optenberg, DrPH
Advertisement
Articles by Scott A. Optenberg, DrPH
Advertisement
Latest Updated Articles
- An Overview Cost-Utility Analysis of Prostate Cancer Screening
Published: November 1st 1995 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Radiotherapy Plus Chemoimmunotherapy Improves Frontline ES-SCLC Prognosis
2
Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers
3
Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC
4
Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs
5
